Daiichi Sankyō (4568) Stock Price, Fundamentals & Analysis
Price
2,929 JPY
+1.7%
Last trade: Sep 25, 2026, 03:30 PM GMT+9
Updated: Sep 27, 2026, 06:31 PM GMT+9
Price history
Over the past year 4568 traded between 2,392 JPY and 4,174 JPY, closing at 2,929 JPY on Sep 25, 2026.
Key statistics
| Market cap | 5.33T JPY |
|---|---|
| P/E ratio (TTM) | 21.4 |
| Forward P/E | 20.4 |
| EPS (TTM) | 136.8 JPY |
| Dividend yield | 3.41% |
| Annual dividend | 100 JPY |
| Ex-dividend date | Sep 29, 2026 |
| Payout ratio | 56% |
| 52-week range | 2,390 – 4,178 |
| 52-week change | -11.1% |
| Price / book | 3.13 |
| Revenue (TTM) | 2.22T JPY |
| Revenue growth (YoY) | 21.1% |
| Gross margin | 68.5% |
| Operating margin | 14.8% |
| Profit margin | 10.9% |
| Return on equity | 14.8% |
| Debt / equity | 29.4 |
| Volume | 6,404,400 |
| Average volume | 6,348,216 |
| Next earnings | Oct 30, 2026 |
| Exchange | Tokyo |
Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 20,171
- Headquarters
- Chuo, Japan
- Website
- daiichisankyo.com
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent.
Overview
What 4568 does
Daiichi Sankyō (4568) is a stock listed on the Tokyo Stock Exchange in the Healthcare sector, specifically in the Drug Manufacturers - General industry. The company manufactures and sells pharmaceutical products in Japan and internationally. Its portfolio includes treatments for cancer (such as Enhertu for HER2-positive breast cancer and solid tumors), blood disorders (Vanflyta for acute myeloid leukemia), and cardiovascular and metabolic conditions (antihypertensive agents, cholesterol-lowering drugs, and anti-platelet agents). It is part of the Nikkei 225 index and operates alongside peers such as Takeda Pharmaceutical (4502) and Chugai Pharmaceutical (4519).
Key numbers explained
- Price of 2,929 JPY: the most recent trading price of one share.
- Market cap of 5.33T JPY: the total market value of all outstanding shares, reflecting the company's size relative to others.
- Trailing P/E ratio of 21.4: the current share price divided by the last 12 months of earnings per share; a higher number can indicate higher investor expectations for future growth.
- Dividend yield of 3.41%: the annual dividend payment expressed as a percentage of the share price, showing the cash return to shareholders.
- Revenue growth of 21.1% year over year: the percentage increase in total sales over the trailing 12 months compared with the prior period.
- Profit margin of 10.9%: the percentage of revenue that remains as profit after all expenses, indicating how efficiently the company converts sales into earnings.
- Debt-to-equity ratio of 29.4%: the proportion of debt relative to shareholders' equity, used to gauge financial leverage and risk.
- Price change over the last 52 weeks of -11.1%: the percentage difference between the current price and the price one year ago, showing the medium-term trend.
What to watch
Investors tracking Daiichi Sankyō (4568) often monitor its pipeline of drug approvals and clinical results, as new product launches or setbacks can affect revenue and stock performance. The company's exposure to international markets and currency fluctuations is another factor, given that it operates both in Japan and abroad. Regulatory decisions on key products, competitive dynamics within the Drug Manufacturers - General industry, and broader healthcare policy changes are general elements that can influence the stock's movement. The next earnings report is scheduled for 30 oct. 2026, which typically provides updated guidance and financial details.
Latest news & filings
No recent headlines.
Frequently asked questions
Does 4568 pay a dividend?
Yes, Daiichi Sankyō (4568) pays a dividend with a yield of 3.41%. The ex-dividend date is 29 sept. 2026, and the company distributes 56% of its earnings as dividends.
What is the 4568 P/E ratio?
The trailing P/E ratio for Daiichi Sankyō (4568) is 21.4, while the forward P/E ratio based on expected earnings is 20.4.
Where can I buy 4568?
Daiichi Sankyō (4568) trades on the Tokyo Stock Exchange. You can buy it through any broker that provides access to Japanese equities.
What sector and industry is 4568 in?
It is in the Healthcare sector, within the Drug Manufacturers - General industry.
What is the market cap of 4568?
The market capitalization of Daiichi Sankyō (4568) is 5.33T JPY.
Related
More on 4568
Track 4568 in your portfolio
Hold 4568 at XTB, IBKR, Tradeville, Revolut or Trading 212? InvestPane brings every broker into one dashboard — allocation, performance and dividends in one place.
Start free